In this episode, we’re joined by Rabia Muqaddam, senior staff attorney at the Center for Reproductive Rights. Muqaddam discusses the Supreme Court's recent decision that preserved access to the abortion pill mifepristone.
The Supreme Court made several recent decisions that impact healthcare, including overturning the Chevron deference and upholding access to the abortion pill mifepristone.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
The Supreme Court sided with the FDA and unanimously ruled to uphold access to abortion pill mifepristone. The decision quells worries about what it might look like if the Supreme Court sided with the physician group — many healthcare leaders feared that if the top court could overturn mifepristone’s FDA approval, the same could happen to other drugs.
Three upcoming Supreme Court decisions have the potential to radically change FDA regulation of medications. The cases, which involve “Chevron deference” and the abortion pill mifepristone, were discussed on a panel during the BIO conference in San Diego.
New York Governor Kathy Hochul signed new legislation that will protect the state's doctors, medical providers and facilitators who prescribe abortion care telehealth services to patients outside of New York from litigation in states where abortion services are banned or restricted.
If a drug’s FDA approval could be overturned by any judge, anywhere, anytime the pharmaceutical industry would be severely impacted. While mifepristone is no blockbuster, a legal precedent allowing courts to overturn the FDA’s approval could be applied to other drugs like blockbuster drugs like Viagra, Humira, or the new diabetes, weight-loss drugs Ozempic or Wegovy.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The current legal landscape makes access to medication abortion crucial in protecting as much access to reproductive healthcare as possible and in protecting healthcare providers’ abilities to do their jobs without fear of prosecution.
The group complains that the FDA never studied the safety of the drugs under the labeled conditions of use.